meta
|
evidence
oncology
Living systematic review and meta-analysis
breast cancer - adjuvant
13
antibody–drug conjugate
trastuzumab emtansine
trastuzumab emtasine plus endocrine therapy
cyclin inhibitor
abemaciclib based treatment
abemaciclib plus endocrine therapy
palbociclib based treatment
palbociclib
palbociclib plus endocrine therapy
HER inhibitor
HER2 inhibitor
neratinib based treatment
neratinib
pertuzumab based treatment
pertuzumab plus trastuzumab
trastuzumab based treatment
docetaxel plus carboplatin with trastuzumab followed by trastuzumab
doxorubicin plus cyclophosphamide followed by docetaxel plus trastuzumab
immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab alone
mTOR inhibitors
everolimus
poly ADP-ribose polymerase (PARP) inhibitor
olaparib